Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis

Thorunn A. Olafsdottir1,2, Fannar Theodors1, Kristbjorg Bjarnadottir1, Unnur Steina Bjornsdottir3,4, Arna B. Agustsdottir1, Olafur A. Stefansson1, Erna V. Ivarsdottir1,5, Jon K. Sigurdsson1, Stefania Benonisdottir1, Gudmundur I. Eyjolfsson6, David Gislason4,7, Thorarinn Gislasson2,8, Steinunn Guðmundsdóttir1, Arnaldur Gylfason1, Bjarni V. Halldorsson1,9, Gisli H. Halldorsson1,10, Thorildur Juliusdottir1, Anna M. Kristinsdottir1, Dora Ludviksdottir1,2,7, Bjorn R. Ludviksson2,10, Gisli Masson1, Kristjan Norland1, Pall T. Onundarson2,11, Isleifur Olafsson12, Olof Sigurardottir2,13, Lilja Stefansdottir1, Gardar Sveinbjornsson1, Vinicius Tragante1,14, Daniel F. Gudbjartsson1,5, Gudmar Thorleifsson1, Patrick Sulem1, Unnur Thorsteinsdottir1,2, Gudmundur L. Norddahl1, Ingileif Jonsdottir1,2* & Kari Stefansson1,2*

Asthma is one of the most common chronic diseases affecting both children and adults. We report a genome-wide association meta-analysis of 69,189 cases and 702,199 controls from Iceland and UK biobank. We find 88 asthma risk variants at 56 loci, 19 previously unreported, and evaluate their effect on other asthma and allergic phenotypes. Of special interest are two low frequency variants associated with protection against asthma; a missense variant in TNFRSF8 and 3' UTR variant in TGFBR1. Functional studies show that the TNFRSF8 variant reduces TNFRSF8 expression both on cell surface and in soluble form, acting as loss of function. eQTL analysis suggests that the TGFBR1 variant acts through gain of function and together with an intronic variant in a downstream gene, SMAD3, points to defective TGFβR1 signaling as one of the biological perturbations increasing asthma risk. Our results increase the number of asthma variants and implicate genes with known role in T cell regulation, inflammation and airway remodeling in asthma pathogenesis.
Asthma is one of the most common chronic diseases and has a substantial impact on the quality of life of both children and adults. Currently, it is estimated that around 300 million people have asthma worldwide and those numbers are predicted to rise in the coming years. Asthma is a syndrome with heterogeneous pathophysiology and different asthma phenotypes differ in age of onset, environmental risk factors, clinical presentation, prognosis, and response to therapies. To further characterize the distinct mechanistic pathways underlying the disease, asthma endotypes have been defined and can broadly be regarded as type 2 (T2) high or T2 low. T2 high asthma is characterized by increased activation of T helper cells of type 2 (Th2), innate lymphoid cells of type 2 (ILC2), and eosinophils. In contrast to T2 high, T2 low endotype is less well defined and is typically characterized by the absence of markers of T2 high disease and has rather been linked with activation of neutrophils, Th1 and/or Th17 cells. This heterogeneity may explain why fewer asthma loci have been identified through genome-wide association studies (GWAS) than in other diseases of similar prevalence. In total, 44 sequence variants (36 in Europeans and 8 in other ancestries) have been reported to associate with asthma in 27 independent GWAS. We have previously discovered common sequence variants in IL33 and it’s receptor IL1RL1 conferring risk of asthma, followed by an identification of a rare loss of function variant in IL33 that protects against asthma, thereby supporting its relevance as pharmacological target for asthma.

Comorbidity between asthma and other allergic diseases (especially allergic rhinitis and atopic dermatitis) has been reported and recent publications have focused on shared risk (especially allergic rhinitis and atopic dermatitis) has been reported and recent publications have focused on shared risk associates with asthma (Table 1). Sixteen of the previously unreported asthma variants with asthma sub-phenotypes (early-/late-onset and allergic asthma) as well as related traits (eosinophil count and allergic diseases).

Results and discussion

Genome-wide meta-analysis. We performed a meta-analysis combining asthma GWAS results from Iceland (n = 16,247 cases, n = 346,486 controls) and the UK biobank (n = 52,942 cases, n = 355,713 controls). The asthma phenotype in both sets was based on physician diagnoses and/or self-reported doctor diagnoses. Association between genotype and phenotype was tested by logistic regression, assuming a multiplicative model (see methods). We used genome-wide significant thresholds dependent on variant annotation and found association with asthma at 55 loci (>1 Mb apart) in addition to the extended HLA region (chr6: 25,000,000–35,000,000, build hg38). Conditional analysis revealed one or more secondary signals (P < 5 × 10^{-8}) at 17 of the 56 loci thus yielding 88 independent signals (Fig. 1, Supplementary Data 1). Based on number of cases and controls, we note that the effective sample size is four times bigger for the UK biobank samples (N = 84,396) than the Icelandic (N = 22,689), hence most of the power comes from the UK biobank samples. The estimated genomic inflation in the two studies (estimated using LD-score regression) is 1.368 for the Icelandic dataset and 1.092 for the UK biobank dataset, reflecting the relatedness of individuals in Iceland which is also the most likely explanation of genomic inflation in UK biobank where 30% of the participants have a relative (third degree or closer) in the UK biobank dataset.

We note that only 4 out of the 88 variants showed significant heterogeneity in effect sizes based on the number of variants tested (P < 0.05/8 = 5.62 × 10^{-4}) and 28 showed nominal heterogeneity (P < 0.05) between the two sample sets demonstrating a good consistency of effect for vast majority of the variants. The observed heterogeneity of the effect estimates is likely due to difference in the phenotype definition and/or ascertainment between the studies, coherent with retrospective studies as reported here. Further, 85 out of the 88 variants (P < 1 × 10^{-16}) had effect size in the same direction in the two cohorts and 44 were at least nominally significant in Iceland showing good replication of effects (Supplementary Data 1).

Of the 88 independent signals, 47 are at 24 previously reported asthma loci, 22 variants at 16 loci have previously been reported for a combined allergic phenotype and 19 variants at 16 loci are previously unreported asthma signals. We note that while this manuscript was under consideration two independent published association of asthma with 9 of those variants as indicated in Table 1. Out of the 47 variants at previously reported loci, 24 were represented by previously reported variants (r^2 ≥ 0.2; Supplementary Data 2) and 23 by previously unreported signals at those loci (r^2 < 0.2; Supplementary Data 3). Furthermore, we replicated 31 out of the 36 reported European asthma loci when adjusting for the 36 variants tested (P < 0.05/36 = 1.4 × 10^{-3}). For two of five non-replicating variants we found other genome wide significant (GWS) variants at the respective loci (Supplementary Data 4).

Forty-one of our 88 variants at 32 loci have not been previously associated with asthma, although 22 variants at 16 loci have previously been reported for a combined allergic phenotype of asthma, hay fever and eczema (Supplementary Data 5).

Altogether, we identified 19 independent signals at 16 loci not previously reported to associate with asthma or the combined allergic phenotype (Table 1). Sixteen of the previously unreported variants were common (Effect Allele Frequency (EAF) ≥ 5%) and three were low frequency variants. None of those variants showed significant (P < 0.05/88 = 5.62 × 10^{-4}) heterogeneity of effects in the two sample sets (Table 1).

Loss of function variant in TNFRSF8. One of the low frequency variants (EAF = 1.2% (ICE)/1.5% (UK)) rs2230624_A is a missense variant p.Cys273Tyr in TNFRSF8 (alias CD30) that associates with reduced asthma risk. The p.Cys273Tyr variant had the greatest protective effects (OR = 0.82, P = 8.27 × 10^{-13}) of the 19 previously unreported variants and in fact there were only 4 out of the 88 asthma variants with greater effect on asthma risk; rs72782676 (intergenic on chr10, OR = 0.63), rs149045797 (intronic variant at IL33 locus, OR = 0.65), rs17272502 (intronic variant at IL2RA locus, OR = 0.80 and rs68161761 (stop-gained variant at FLG locus, OR = 1.24). The rs2230624_A variant is a singleton (all LD < 0.4; Fig. 2a) and is predicted by PROSITE database to disrupt a disulfide bond between Cys in positions 273 and 259 in the extracellular domain of the protein. CD30 is expressed on the surface of activated lymphocytes and eosinophils and has been implicated in activation, proliferation and apoptosis via NFkβ activation.
bite size<sup>23</sup>. Increased soluble CD30 (sCD30) in serum has been associated with increased severity of asthma in children<sup>24</sup> and CD30 knock-out mice are protected against asthma<sup>25</sup>. Therefore, we postulate that the missense p.Cys273Tyr in TNFRSF8 that associates with decreased asthma risk reduces the function of CD30. In order to investigate this, we over-expressed wild-type (WT) CD30 or the p.Cys273Tyr variant in HeLa cells and compared levels of CD30 protein generated. CD30 is expressed as a precursor protein that undergoes post-translational modification, that turns it into the mature form of the protein<sup>26,27</sup>. Lysates from cells expressing the p.Cys273Tyr variant had higher ratio of the precursor form to the mature form than that observed in cells expressing the WT CD30 (P = 4.2 × 10<sup>−7</sup>, two-tailed paired t-test; Fig. 2b and Supplementary Fig. 1). Moreover we observed both a lower cellular surface expression on p.Cys273Tyr than WT CD30 cells (P = 7.4 × 10<sup>−5</sup>, two-tailed paired t-test, Fig. 2c) and a significantly lower amount of sCD30 in the culture supernatants of cells expressing the p.Cys273Tyr variant (P = 5.5 × 10<sup>−4</sup>, two-tailed paired t-test, Fig. 2d). In line with this, cell surface expression of CD30 was significantly lower on in vitro stimulated peripheral blood mononuclear cells (PBMCs) derived from p.Cys273Tyr heterozygote carriers (P = 1.5 × 10<sup>−2</sup>, two-tailed Wilcoxon matched-pairs signed rank test; Fig. 2e). We recruited six p.Cys273Tyr homozygote and matched non-carriers and measured CD30 surface expression both on stimulated PBMCs and Epstein-Barr virus transformed lymphoblasts. Surface expression of CD30 tended to be lower on EBV transformed lymphoblasts from homozygous carriers than from matched non-carriers (P = 0.063, two-tailed Wilcoxon matched-pairs signed rank test), whereas no difference was detected when comparing stimulated PBMCs from homozygous carriers to matched non-carriers (P = 0.22, two-tailed Wilcoxon matched-pairs signed rank test) (Supplementary Fig. 2). However, these results warrant further investigation with larger number of homozygotes especially because of the inherent variance of the PBMC stimulation assay. Together our data suggest that the missense variant, leading to the disruption of a disulfide bond between Cys in positions 273 and 259, reduces trafficking of the protein to the cell surface. Furthermore, reduced levels of sCD30 were observed in the cell culture supernatant of in vitro stimulated PBMCs from heterozygote carriers (P = 3.1 × 10<sup>−5</sup>, two-tailed Wilcoxon matched-pairs signed rank test) compared with those from non-carriers (Fig. 2f). This is consistent with reduced surface-expression although an effect of the variant on the CD30 shedding itself cannot be excluded<sup>28</sup>.

**Gain of function variant in TGFBR1.** Another low frequency variant of special interest, is a 3 prime UTR variant, rs41283642_T (EAF = 1.9% (ICE)/3.4% (UK)), in TGFBR1 that associated with reduced asthma risk (P = 2.16 × 10<sup>−10</sup>, OR = 0.89). eQTL analysis showed that in blood the variant associated with 15.2% increase in TGFBR1 expression per allele (P = 7.24 × 10<sup>−101</sup>, effect = 1.18 SD, which is the most significant eQTL for TGFBR1; Fig. 3a, b, Supplementary Data 6). rs41283642_T changes a recognition site for microRNA (miR) miR-142-3p (Fig. 3c). miR-142-3p has previously been shown by others<sup>29</sup> to bind to the 3 prime UTR site in TGFBR1 transcripts leading to increased TGFBR1 expression and through that protection against asthma.

**Unreported common asthma risk variants.** Four of the 16 previously unreported common variants are missense, rs2228552_T in
### Table 1: Previously unreported loci associated with asthma in Iceland – UK biobank meta-analysis.

| Lead SNP | chr:Position | Effect allele | Position | Allele (EA/OA) | EAF % (ICE/UK BB) | Gene | Coding change | OR (95% CI) |
|----------|--------------|---------------|----------|----------------|-------------------|------|---------------|-------------|
| rs2230624 | chr1:12115601 | A/G | 1.2/1.5 | MISSENSE | Cys273Tyr/Cys162Tyr | 0.82 (0.78–0.86) | ICE | Downstream | 0.94 (0.93–0.96) |
| rs2228552 | chr1:31699894 | T/G | 68.3/64.3 | MISSENSE | Thr62Lys/Thr52Met | 1.04 (1.02–1.05) | ICE | Intron | 0.94 (0.93–0.96) |
| rs2296618 | chr1:198697103 | G/A | 14.4/13.5 | Downstream | | | | |
| rs7626218 | chr3:177134250 | T/A | 41.1/39.5 | MISSENSE | | 1.07 (1.06–1.12) | ICE | Intron | 0.96 (0.95–0.97) |
| rs1800797 | chr7:22726602 | G/A | 52.2/58.0 | 1.05 | 2.6E-08 | ICE | Intron | 0.86 |
| rs34173062 | chr8:144103704 | A/G | 6.6/7.2 | Missense | Cys273Tyr/Cys162Tyr | 1.04 (1.03–1.05) | ICE | Downstream | 0.93 (0.92–0.95) |
| rs41283642 | chr9:99153605 | T/C | 1.9/3.4 | 1.03 | 2.16E-10 | ICE | Intron | 0.05 |
| rs7961712 | chr12:94211187 | A/G | 86.3/85.0 | MISSENSE | Ser17Fuc/Ser17Phe | 1.15 | ICE | Intron | 0.83 |
| rs34939984 | chr16:27234391 | T/C | 40.1/35.9 | 1.06 | 2.83E-11 | ICE | Intron | 0.8 |
| rs6498021 | chr16:27403057 | G/T | 85.3/86.0 | MISSENSE | Ser17Fuc/Ser17Phe | 1.08 | ICE | Intron | 0.45 |
| rs117552144 | chr19:3136093 | T/C | 5.3/6.7 | 1.09 | 6.7E-10 | ICE | Intron | 0.74 |

**Results are shown for the combined sample-sets of Iceland and the UK BB.**

*P* < 0.05 represents the statistical significance between the two sample-sets. Gene indicates the most likely candidate gene at the locus as described in Supplementary Data 7.

**Effect allele,** **other allele,** **EAF** effect allele frequency

**ICE** Iceland, **OA** other, **OR** odds ratio

---

**Signals at known asthma loci.** Among the 24 previously identified loci were IL1RL1/IL18R1, GATA3, TLR1, TSLP, HLA, IL4/IL5/IL13, RORA, GSDMB, SMAD3, and IL33. Our top signal at the SMAD3 locus, rs72743461_A, correlated with reported asthma signals (16, 124). Our top signal at the HLA region, rs6498021_G, was highly correlated (r² = 0.8) with the top eQTL for increased IL18R1 expression in fibroblasts (Supplementary Data 6). The SMAD3 locus have been associated with asthma in candidate gene studies but not in GWAS. Biologicals targeting IL4R show promise in the treatment of persistent asthma but the role of IL21R in asthma has been less studied. Other loci of interest include NPN1, TNFAIP8, FADS1, GNA15, and IL6. Taken together, based on analysis of coding variants, eQTLs in different tissues, enhancer and promoter signals in CD4+ Th cells we found evidence of a single candidate gene for 8 out of the 19 previously unreported asthma variants (Supplementary Data 9).

**Association of asthma variants with eosinophil count.** We have previously used the well-established link between eosinophilic airway inflammation and asthma to discover common sequence variants in IL1RL1 and IL33 that associate strongly with blood eosinophil counts and risk of asthma. Therefore, we tested the association of our 88 asthma variants with eosinophil blood counts in Iceland and UK biobank. Of those, 69 associate significantly with eosinophil count after adjusting for the number of...
variants tested, with the asthma risk allele associating with higher eosinophil count for 67 of the variants \( (P < 0.05/93 = 5.4 \times 10^{-4}) \), Supplementary Data 11). Among the 20 variants that did not associate with eosinophil count and deviate from the overall correlation between asthma risk and eosinophil count are variants at the filaggrin family member FLG/HRNR locus, suggesting their role in non-eosinophilic asthma (Supplementary Fig. 3).

**Effect of asthma variants on different asthma sub-phenotypes.**

Given the known heterogeneity of asthma we tested the effect of the asthma variants on three asthma sub-phenotypes, allergic asthma (AA), early (EOA) and late (LOA) onset asthma. Overall, the effects of the 88 asthma variants were similar on the sub-phenotypes although for some of the variants (e.g. at FLG/HRNR locus) the effect was stronger on EOA than LOA (Fig. 4a). Further, the effect of IL33 \( (rs149045797) \) variant was largest on EOA \( (OR = 0.53, P = 3.8 \times 10^{-9}) \) followed by LOA \( (OR = 0.71, P = 5.1 \times 10^{-9}) \) with smallest effect on AA \( (OR = 0.93, P = 0.70) \); Fig. 4 and supplementary Data 12). This variant is fully correlated \( (r^2 = 1) \) with a loss of function variant \( (rs146597587) \) previously reported to associate with reduced IL33 mRNA expression and asthma risk and in line with the results reported here, the largest effect was observed in young children who were hospitalized at least 4 times before the age of 6 years due to asthma exacerbation \( (OR = 0.24, P = 0.04) \)\(^9\). However, 58% of those young children had atopic diagnosis before 6 years of age\(^8\) indicating that the IL33 association is driven by severe asthma rather than non-AA exclusively. We note that we lack information on AA for a large part of our samples, especially in the UK biobank samples where only 542 (1% of all asthma cases) have this diagnosis and there is an overlap both with the early and late onset asthma cases. Therefore, the IL33 association with asthma severity in AA and non-AA warrants further investigation.

Conversely, the effect of the FLG variant was stronger on AA than on LOA and the effect of a variant at the GATA3 locus was stronger on AA than on either EOA or LOA (Fig. 4c). These results point to a partly distinct genetic architecture behind the three asthma phenotypes tested in our analysis in line with the clinical heterogeneity. Our results show that certain sequence variants have stronger effect in EOA than LOA indicating that genetics may play a larger role in EOA.

**Genetic correlation between asthma and allergic phenotypes.**

Recently, 136 variants were reported to associate with a combined allergic phenotype (asthma, hay fever and/or eczema)\(^11\). The overall effects of these 136 allergy variants correlated well with the effects in our asthma meta-analysis, although several markers (e.g. TSLP, GATA3, SMARCE1) demonstrated weak correlation (Supplementary Fig. 4). This is in line with reported genetic correlation between asthma and allergic diseases (hay fever/allergic rhinitis or eczema)\(^6\).

We also tested the 88 independent asthma variants for association with different allergic phenotypes, (Supplementary Table 1). Interestingly, the effects of these variants on asthma
correlated significantly with their effects on allergic rhinitis (AR; \( P = 3.1 \times 10^{-13}, r^2 = 0.68 \); Supplementary Fig. 5a) but not with atopic dermatitis (AD; \( P = 9.80 \times 10^{-2}, r^2 = 0.18 \); Supplementary Fig. 5b). Out of the 88 asthma loci, two variants at the same locus, a loss of function variant in \( FLG \) (rs61816761) and intergenic variant (rs12123821, close to \( HRNR \)) had greatest effect on AD (Supplementary Data 12). Further, significant correlation was observed between effects of the asthma variants on asthma and on nasal polyps (NP) as well as on chronic rhinosinusitis (CRS) with nasal polyps (NP) as well as on chronic rhinosinusitis (CRS) with or without nasal polyps (CRSsNP) but not with CRS without NP (CRSwNP) in agreement with differences in the pathogenesis of these closely related phenotypes\(^{47} \) (Supplementary Fig. 5c–f). Variants at \( IL33, GATA3, BACH2, HLA \) and \( TLSLP \) loci significantly associated with \( >3 \) asthma/allergic phenotypes \((P < 0.05/(88 \times 9) = 5.7 \times 10^{-5})\), adjusted for number of variants and phenotypes tested; (Supplementary Data 12), most of which are important for generation and function of ILC2 and Th2\(^{48} \). Taken together, the correlation of effects of the 88 asthma variants was stronger with respiratory allergic phenotypes of T2 than with AD or the Th1 driven CRSsNP. However, we observed substantial overall genetic correlation between asthma and AD as well as between asthma and allergic rhinitis indicating that other variants than the 88 reported here play a significant role in the genetic link between asthma and AD (Supplementary Table 2). Since this is a retrospective study, not designed to study co-morbidities of asthma and allergic diseases, we cannot exclude that some of the overlapping association of certain sequence variants with e.g. asthma and AD might be due to overlap of the two phenotypes. However, only 980 out of 16,247 asthma cases in Iceland had the AD diagnosis (6%) while AD was hardly reported as a single disease in UK biobank, making it impossible to accurately define asthmatics without AD.

**Pathway analysis.** Pathway analysis was performed using DEPICT\(^{49} \) to search for the biological connectivity between the asthma association signals. DEPICT prioritized 71 (FDR < 0.05) known genes (Supplementary Data 13) and identified 787 significantly (FRD < 0.01) enriched gene sets, the majority involved in T cell biology, mainly implicating CD4\(^+ \) T cells, regulation of their activation, responses and physiology (Supplementary Data 14).

In summary, our study considerably expands the number of asthma susceptibility loci and confirms many previous findings. The results highlight the role of Th cells in asthma in line with unbalanced T cell regulation reported to play a critical role in...
Fig. 4 Effect of asthma associating variants in asthma sub-phenotypes. Early onset asthma (EOA), Late Onset Asthma (LOA) and Allergic Asthma (AA). The x-axis and the y-axis show the logarithm of the estimated odds ratios for a EOA and LOA, b AA and EOA, and c AA vs LOA, respectively. All effects are shown for the asthma risk increasing allele based on meta-analysis of the Icelandic and the UK BB sample sets. Error bars represent 95% confidence intervals. The red line represents results from a simple linear regression through the origin using MAF (1-MAF) as weights and the gray line indicates the reference line with slope = 1. The weighted correlation coefficients (r) and P values (t-test) are shown in the graphs. Source data are provided as a Source Data file.

Methods

Study sample sets for asthma, allergy phenotypes, and eosinophil count

Asthma in the UK biobank was defined as ICD10 diagnoses in fields 41202 or 41204, including anyone of J45.0, J45.1, J45.8, J45.9, and J46 and/or self-reported by the non-cancer illness code, self-reported during verbal interview (data-field 20002) with a code for asthma (1111).

Icelandic asthma patients over 18 years of age were recruited who attended an asthma clinic or emergency room at the National University Hospital of Iceland or the Iceland Medical Center (Laeknasetir) during the years 1977 to 2017. Asthma diagnosis was based on a combination of physician’s diagnosis and ICD10 diagnosis, including anyone of J45.0, J45.1, J45.8, J45.9, and J46 and/or self-reported by a positive reply to the question: has a doctor confirmed your asthma diagnosis. Atopy status determined by skin prick testing and age of onset was available for part of the asthma cohort both in Iceland and UK biobank. Early onset was defined as first diagnosis ≤17 years of age and late onset as first diagnosis >17 years of age. Late onset asthma diagnosis from Iceland contains both where the first diagnosis was at or after 18 years of age and where the first diagnosis is unknown. In total we had 16,247 asthma cases and 346,486 controls from Iceland and 32,947 cases and 355,713 controls from the UK biobank. Estimating the effective number of cases and controls, respectively, and GC is the genomic adjustment effective number of cases as 2 × Na × Nc / (Na + Nc)54. Genotyping of UK biobank samples was performed using a custom-made Affymetrix chip, UK BiLEVE Axiom55, and with the Affymetrix UK Biobank Axiom array.56 Imputation was performed by the Wellcome Trust Centre for Human Genetics, using the Haplotype Reference Consortium (HRC) and the

Whole-genome sequencing and imputation. The GWASs in Iceland were performed between the years 1993 and 2015. The circulating eosinophil counts were standardized to a standard normal distribution using quantile-quantile standardization and then adjusted for sex, year of birth, and age at measurement, as previously described53. A total of 251,307 Icelanders with eosinophil counts were included in the study. In the UK biobank we had eosinophil counts for a total of 396,822 individuals that were adjusted for sex, year of birth, age at measurement, and the first 40 principal components, then inverse normal transformed.

All participating individuals who donated blood signed informed consent. The personal identities of participants were encrypted using a third-party system approved and monitored by the Icelandic Data Protection Authority.53 The study was approved by the National Bioethics Committee in Iceland (Approval no. VSN 14-099).

We obtained eosinophil counts from three of the largest laboratories in Iceland (measurements performed between the years 1993 and 2015). The circulating eosinophil counts were standardized to a normal distribution using quantile-quantile standardization and then adjusted for sex, age, and at measurement, as previously described55. A total of 251,307 Icelanders with eosinophil counts were included in the study. In the UK biobank we had eosinophil counts for a total of 396,822 individuals that were adjusted for sex, year of birth, age at measurement, and the first 40 principal components, then inverse normal transformed.

All participating individuals who donated blood signed informed consent. The personal identities of participants were encrypted using a third-party system approved and monitored by the Icelandic Data Protection Authority53. The study was approved by the National Bioethics Committee in Iceland (Approval no. VSN 14-099).

We obtained eosinophil counts from three of the largest laboratories in Iceland (measurements performed between the years 1993 and 2015). The circulating eosinophil counts were standardized to a normal distribution using quantile-quantile standardization and then adjusted for sex, age, and at measurement, as previously described55. A total of 251,307 Icelanders with eosinophil counts were included in the study. In the UK biobank we had eosinophil counts for a total of 396,822 individuals that were adjusted for sex, year of birth, age at measurement, and the first 40 principal components, then inverse normal transformed.

All participating individuals who donated blood signed informed consent. The personal identities of participants were encrypted using a third-party system approved and monitored by the Icelandic Data Protection Authority53. The study was approved by the National Bioethics Committee in Iceland (Approval no. VSN 14-099).

We obtained eosinophil counts from three of the largest laboratories in Iceland (measurements performed between the years 1993 and 2015). The circulating eosinophil counts were standardized to a normal distribution using quantile-quantile standardization and then adjusted for sex, age, and at measurement, as previously described55. A total of 251,307 Icelanders with eosinophil counts were included in the study. In the UK biobank we had eosinophil counts for a total of 396,822 individuals that were adjusted for sex, year of birth, age at measurement, and the first 40 principal components, then inverse normal transformed.
UK10K haplotype resources. This yields a total of 96 million imputed variants, however only 27 million variants imputed using the HRC reference set passed the quality filters used in our study.

**Association testing and meta-analysis of disease phenotypes.** Logistic regression was used to test for association between variants and disease, assuming a multiplicative model, treating disease status as the response and expected genotype counts from imputation as covariates. We used LD score regression\textsuperscript{13} to account for inflation in test statistics due to cryptic relatedness and stratification. We chose to include related individuals in the analysis as removing related individuals in the heavily genotyped Icelandic population would lead to the removal of most participants. Including related individuals while accounting for genomic control has proven to be a robust method\textsuperscript{16,26} that does not create false positives as observed in the QQ plots (Supplementary Fig. 6; especially stratified on frequency). Software developed at deCODE genetics\textsuperscript{26} was used to test for association in both populations. Sex, age, and county of origin were included in the logistic regression for the Icelandic dataset, and sex, age, and the first 40 principal components for the UK biobank dataset. Imputation information criteria was set so that variants below 0.8 were excluded from the analysis.

Variants were mapped to NCBI Build38 positions and subsequently variants in the UK biobank imputation dataset were matched to the variants in the Icelandic dataset based on allele variation. Mantel-Haenszel model\textsuperscript{16} was used to combine the results from the different study groups in which the groups were assumed to have a common OR but were allowed to have different population frequencies for alleles in different populations. A likelihood ratio test was used to test heterogeneity by comparing the null hypothesis of the effect being the same in all populations to the alternative hypothesis of each population having a different effect. Heterogeneity was quantified by I\textsuperscript{2} statistics which lies between 0 and 100\% and describes the proportion of total variation in study estimates that is due to heterogeneity. Variants that were included in the genome-wide association analysis and associations were considered significant if the p-value in the combined dataset was below a weighted genome-wide significance threshold based on variant annotation.

With 32,463,443 sequence variants being tested the weights given in Sveinbjornsson et al.\textsuperscript{16} were used to control the family-wise error rate (FWER)\textsuperscript{60}. The adjusted significance thresholds are 2.6 × 10\textsuperscript{−7} for variants with high impact (N = 8,464), 5.1 × 10\textsuperscript{−8} for variants with moderate impact (N = 149,983), 4.6 × 10\textsuperscript{−9} for low-impact variants (N = 2,283,889), 2.3 × 10\textsuperscript{−9} for other variants in DNaSe I hypersensitivity sites (N = 3,913,058) and 7.9 × 10\textsuperscript{−10} for all other variants (N = 26,108,038). Approximate conditional analyses (COJO), implemented in the GCTA software\textsuperscript{61} were performed on lead variants, deconfounding secondary signals.

**Enhancer and transcription start site analysis.** Variants in linkage disequilibrium (LD) with the lead variants at the previously unreported loci were identified on the basis of in-house genotype data using r\textsuperscript{2} > 0.8 for pairwise comparison of the nearest 100,000 variants to define an LD class. These variants were then annotated, see results in Supplementary Data 9. Chromatin states for CD4 + T-cells were obtained through ChromHMM analyses of available epigenome data from NIH Roadmap Epigenome Mapping Consortium for 11 histone marks analyzed by ChIP-seq, together with open chromatin regions analysed by DNase-seq, integrated into 25 discrete chromatin states\textsuperscript{62} downloaded from [http://www.roadmapepigenomics.org]. The association variants were then annotated for chromatin states involving enhancers (EnhA1, A2, W1, or W2) or DHS sites (DNA hypershensitivity sites, reflecting open chromatin configuration). To identify enhancer-gene targets, we made use of the joint effect of multiple enhancers (JEME) resource\textsuperscript{63}. Variants within or proximal (±25 bp) to transcriptional start sites\textsuperscript{64} were hummed on the basis of CAGE sequencing data derived from the Fantom5 project\textsuperscript{65} downloaded from [fantom.gsc.riken.jp/5/data]. 3’ UTR variants in predicted miRNA target sites were annotated by making use of data from Targetscan v7.2\textsuperscript{66} targetscan.org.

**Generation of CD30 variants.** Full-length CD30 cDNA (NM_001243) in pCMV6-Entry Myc-DDK tagged mammalian expression vector was obtained from OriGene (RC219816). Cys273Tyr mutant plasmid was generated using Q5 Site-Directed Mutagenesis kit (New England BioLabs, E0551S) with mutagenesis primers F-5’-AAGGAGGATATGAGGAAAC-3’ and R-5’-CTCCCAAGAGGCTATCGC-3’ (Supplementary Table 4). Plasmids were transformed into NEB Stable Competent E.coli (New England BioLabs, C3040H) and spread on LB agar plates containing 25 µg/ml kanamycin. Colonies were expanded in LB medium containing 25 µg/ml kanamycin. Plasmids were purified using Qiagen plasmid maxi kit (Qiagen, 12163), following the manufacturer’s protocol. The sequences of WT and Cys273Tyr plasmids were confirmed by Sanger sequencing.

**Expression of CD30 and CD30 cDNA Cys273Tyr in Hela cells.** One day prior to transfection 0.1 × 10\textsuperscript{6} Hela cells (Public Health England 93021013) were seeded in DMEM medium (ThermoFisher 11995-065) supplemented with 10% fetal bovine serum (ThermoFisher 10010-064) and 50 units/ml penicillin and 50 µg/ml streptomycin (ThermoFisher 15070-063). Cells were incubated at 37 °C with 5% CO\textsubscript{2} and humidified by 100% humidity.

After 24 hours cells were transfected using FuGENE®HD reagent (Promega E2312) following manufacturer’s protocol. In short DNA was diluted in OptiMem medium (ThermoFisher 31985-047) and FuGENE®HD reagent was added at a FuGENE®HD reagent: DNA ratio 3:1. The day after transfection media was removed from cells and they were washed once with PBS. Cells were dislodged from wells by incubation for 5 min at 37 °C using PBS + 2 µM EDTA. Cells were collected and spun down at 300 × g for 5 min, resuspended in 1 ml PBS + 2% FBS and spun down again. Cell pellet was snap frozen and kept in −80 °C for subsequent lysis preparation.

**Hela lysis preparation.** Cells were lysed using 100 µl of RIPA buffer with 1:100 Halt protease and inhibitor cocktail (Thermo Scientific 78430). Lysates were kept on ice for 10 min and subsequently spun down at 4 °C for 15 min at 14,000 × g. Total protein concentration in lysates was estimated using the Pierce BCA protein assay kit (ThermoFisher 23227).

**EBV cell culture.** EBV transformed lymphoblasts from homzygous carrier and non-carrier of Cys273Tyr were cultured in RPMI1640 (ThermoFisher 61870-036) supplemented with 10% fetal bovine serum (ThermoFisher 10010-064), 50 units/ml penicillin, 50 µg/ml streptomycin (ThermoFisher 10570-063) and 20 mM HEPES (ThermoFisher 15630-056). Cells were incubated at 37 °C and 5% CO\textsubscript{2} in a humidified incubator. The cells were seeded at 5 × 10\textsuperscript{4} cells/ml in fresh media 2 days prior to harvesting.

**Simple Western by size quantification of CD30 signal in Hela.** Total of 0.05 mg/ml Hela lysate was run in WES from Protein Simple following manufacturer’s protocol using WES 12-230 kDa separation module (Biotectne SM-W002-1). Antibody used: Purified mouse anti human CD30 (clone BerH8) (BD Biosciences cat: 558527) 1:100 dilution. Precursor CD30 signal was quantified as a 143 kDa peak and mature CD30 signal as a 207 kDa peak. As a normalization for total protein content, individual Western blots were standardized after immunodetection of total protein (β-actin) and followed manufacturer’s protocol. CD30 precursor and mature signals were normalized to total protein.
Flow cytometry analysis on Hela, EBV, and stimulated PBMCs. EBV cells were harvested, counted and diluted to 1 × 10⁶ cell/ml plated in a 96 well V bottom plate. Cells were then stained with primary antibodies against PE/Cy5 anti-human CD30 (Biolegend 333918), clone BY88 reported to bind at similar amino acid residues as Ber-H6⁷⁰ that has been shown to bind epitope at the N-terminus of the peptide chain up to amino acid residue 93⁷⁷ thus unaffected by a possible effect of our variant at amino acid 273. The cells were analyzed for expression of CD30 by FACS (gating strategy shown in Supplementary Fig 7). Cryopreserved PBMC were thawed and and plated for culture in RPMI1640 (ThermoFisher 61870-036) supplemented with 10% fetal bovine serum (ThermoFisher 10098-036), 20 mM HEPES (ThermoFisher 15630056) and 30 IU/ml IL-2 (R&D Systems AAL202) in a 24-well TCR plate and rested overnight. Cells were then stimulated for 48 hours with anti CD3/CD28 dynabeads (ThermoFisher 11131D). At 48 hours were harvested and stained with directly PE conjugated antibody (Biolegend 333906clone: BY88) and analyzed for expression of CD30 by FACS. Two-tailed Wilcoxon matched-pairs signed rank test was used to test for significant differences in cell surface expression of CD30 on PBMCs and EBVs. Two-tailed paired t-test was used to test for significant differences in cell surface expression of CD30 on HeLa cells.

Soluble CD30 measured by ELISA. Soluble CD30 was measured by sandwich ELISA (ThermoFisher BMS240INST) in a 1/4 dilution and according to manufacturer’s instructions. Two-tailed Wilcoxon matched-pairs signed rank test was used to test for soluble CD30 in levels of sCD30 from PBMCs and EBVs. Two-tailed paired t-test was used to test for significant differences in cell surface expression of CD30 on HeLa cells.

Pathway analysis. We used DEPICT²⁰ to (1) prioritize candidate causal genes at associated loci and (2) highlight enriched pathways where genes at associated loci are highly expressed. DEPICT uses gene expression data derived from a panel of 77,840 mRNA expression arrays together with 14,461 existing gene sets based on molecular pathways derived from experimentally verified protein–protein interactions,⁷⁷ gene-phenotype relationships from the Mouse Genetics Initiative,⁷³ Reactome pathways,⁷⁺ KEGG pathways,⁷⁵, and Gene Ontology (GO) terms.⁷⁶ DEPICT reconstitutes these 14,461 gene sets by calculating for each gene the probability of membership in each gene set, based on similarities across the expression data. Using these membership probabilities and a set of trait-associated loci, DEPICT tests whether any of the 14,461 reconstituted gene sets are enriched for genes at the trait-associated loci, and prioritizes genes that share predicted functions with genes at other trait-associated loci. We ran DEPICT using all 88 asthma-associated variants.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The sequence variants from the Icelandic population whole-genome sequence data have been deposited at the European Variant Archive under accession code PRJEB15197. The sequence variants from the Icelandic population whole-genome sequence data have been deposited at the European Variant Archive under accession code PRJEB15197. The sequence variants from the Icelandic population whole-genome sequence data have been deposited at the European Variant Archive under accession code PRJEB15197.

Received: 21 December 2018; Accepted: 5 December 2019; Published online: 20 January 2020

References
1. Dharmage, S. C., Perret, J. L. & Custovic, A. Epidemiology of asthma in children and adults. *Front. Pediatr.* 7, 246 (2019).
2. Lambrecht, B. N. & Hammad, H. The immunology of asthma. *Nat. Immunol.* 16, 45–56 (2015).
3. Kuruvilla, M. E., Lee, F. E. & Lee, G. B. Understanding asthma phenotypes, endotypes, and mechanisms of disease. *Clin. Rev. Allergy Immunol.* 56, 219–232 (2019).
4. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* 42, D1001–D1006 (2014).
5. Vicente, C. T., Revez, J. A. & Ferreira, M. A. R. Lessons from ten years of genome-wide association studies of asthma. *Clin. Transl. Immunol.* 6, e165 (2017).
6. Zhu, Z. et al. A genome-wide cross-trait analysis from UK Biobank highlights the shared genetic architecture of asthma and allergic diseases. *Nat. Genet.* 50, 857–864 (2018).
7. Demenais, F. et al. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer markers. *Nat. Genet.* 50, 42–53 (2018).
8. Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat. Genet.* 41, 342–347 (2009).
9. Smith, D. et al. A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. *PLoS Genet.* 15, e1006659 (2019).
10. Pinart, M. et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. *Lancet Respir. Med.* 2, 131–140 (2014).
11. Ferreira, M. A. et al. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nat. Genet.* 49, 1752–1757 (2017).
12. Neale Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* 47, 291–295 (2015).
13. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203–209 (2018).
14. Shrine, N. et al. Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. *Lancet Respir. Med.* 7, 20–34 (2019).
15. Johansson, A., Rask-Andersen, M., Karlsson, T. & Ek, W. E. Genome-wide association analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema. *Hum. Mol. Genet.* 1–20 (2019).
16. Pickrell, J. K. et al. Detection and interpretation of shared genetic influences on 42 human traits. *Nat. Genet.* 48, 709–717 (2016).
17. Sigrist, C. J. et al. New and continuing developments at PROSE. *Nucleic Acids Res.* 41, D344–7 (2013).
18. Chiarle, R. et al. CD30 in normal and neoplastic cells. *Clin. Immunol.* 90, 157–164 (1999).
19. Hogan, L. E. et al. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. *PLoS Pathog.* 14, e1006856 (2018).
20. Wright, C. W., Rumble, J. M. & Duckett, C. S. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. *J. Biol. Chem.* 282, 10252–10262 (2007).
21. Berro, A. L. Perry, G. A. & Agrawal, D. K. Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. *J. Immunol.* 173, 2174–2183 (2004).
22. Aslde, W. J. et al. The allelic landscape of human blood cell trait variation and links to common complex disease. *Cell 167*, 1413–1429 e19 (2016).
23. Jones, A. V. et al. GWAS of self-reported mosquito bite size, skin tightness and attractiveness to mosquitoes implicates immune-related predisposition loci. *Hum. Mol. Genet.* 26, 1391–1406 (2017).
24. Heshmat, N. M. & El-Haddad, E. S. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. *Pediatr. Allergy Immunol.* 17, 297–303 (2006).
25. Polte, T., Behrendt, A. K. & Hansen, G. Direct evidence for a critical role of CD30 in the development of allergic asthma. *J. Allergy Clin. Immunol.* 118, 942–948 (2006).
26. Nawrocki, J. F., Kirsten, E. S. & Fisher, R. I. Biochemical and structural properties of a Hodgkin’s disease-related membrane protein. *J. Immunol.* 141, 672–680 (1988).
27. Freese, F. et al. Biochemical characterisation and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines. *J. Immunol.* 139, 2081–2087 (1987).
28. McDermott, M. F. et al. Germline mutations in the extracellular domains of the 35 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell 97*, 133–144 (1999).
29. Lei, Z. et al. MIR-142-3p represses TGF-beta-induced growth inhibition through repression of TGFBetaR1 in non-small cell lung cancer. *FASEB J.* 28, 2696–2704 (2014).
30. Maes, T. et al. Asthma inflammatory phenotypes show differential microRNA expression in sputum. *J. Allergy Clin. Immunol.* 137, 1433–1446 (2016).
31. Grasella, S. & Bauer, B. J. Collagen XVI in health and disease. *Matrix Biol.* 32, 64–73 (2013).
32. Nomura, A. et al. Increases in collagen type I synthesis in asthma: the role of eotaxin and transforming growth factor-beta. *Clin. Exp. Allergy* 32, 860–865 (2002).

33. Wang, Z., Potter, C. S., Sundberg, J. P. & Hogenesch, H. SHARPIN is a key regulator of immune and inflammatory responses. *J. Cell. Mol. Med.* 16, 2271–2279 (2012).

34. HogenEsch, H. et al. A spontaneous mutation characterized by chronic pulmonary inflammation in C57BL mice. *Epigenetics* 4, 192–198 (2009).

35. Seymour, R. E. et al. Spontaneous mutations in the mouse Sharpin gene result in multorgan inflammation, immune system dysregulation and dermatitis. *Genes Immun.* 8, 416–421 (2007).

36. Rosa-Rosa, L., Zimmermann, N., Bernstein, J. A., Rothenberg, M. E. & Zhang, H. et al. Association of IL4R gene polymorphisms with asthma in Chinese populations. *Hum. Mutat.* 28, 1046 (2007).

37. Wenzel, S. E. et al. IL4R alpha mutations are associated with asthma exacerbations and mast cell/ligase expression. *Am. J. Respir. Crit. Care Med.* 175, 570–576 (2007).

38. Zhang, H. et al. Association of IL4R gene polymorphisms with asthma in a Saudi Arabian population. *Ann. Thorac. Med.* 9, 81–86 (2014).

39. Fajt, M. L. & Wenzel, S. E. Development of new therapies for severe asthma. *Allergy Asthma Immunol. Res.* 18, 52 (2016).

40. Yoshimura, A. & Muto, G. TGF-beta function in immune suppression. *Immunol. Lett.* 169, 145–152 (2015).

41. Pers, T. H. et al. Biological interpretation of genome-wide association studies of asthma severity. *Nat. Genet.* 47, 17 (2015).

42. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic population. *Nat. Genet.* 47, 435–444 (2015).

43. Kristjansson, R. P. et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. *Nat. Genet.* 51, 267–276 (2019).

44. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. *J. Natl Cancer Inst.* 22, 719–748 (1959).

45. Svenssonjsson, G. et al. Weighting sequence variants based on their annotation increases power of whole-genome association studies. *Nat. Genet.* 48, 314–317 (2016).

46. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* 44, 375–381 (2012).

47. Loh, P. R. et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat. Genet.* 47, 284–290 (2015).

48. Benonisdottir, S. et al. Epigenetic and genetic components of height regulation. *Nat. Commun.* 7, 13490 (2016).

49. Oskarsson, G. R. et al. A truncating mutation in EPOR leads to hypersensitivity to erythropoietin with normal haemoglobin. *Commun. Biol.* 1, 49 (2018).

50. Kehr, B. et al. Diversity in non-repetitive human sequences not found in the reference genome. *Nat. Genet.* 49, 588–593 (2017).

51. Oskarsson, G. R. et al. Integrative analysis of 111 reference human epigenomes. *Nature* 518, 317–330 (2015).

52. Cao, Q. et al. Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines. *Nat. Genet.* 49, 1428–1436 (2017).

53. The, F. C. et al. A promoter-level mammalian expression atlas. *Nature* 507, 462 (2014).

54. Agarwal, V., Bell, G. W., Nam, J. W. & Bartel, D. P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 4, e1–34 (2015).

55. Leca, G., Vita, N., Maiza, H., Fasseu, M. & Bensussan, A. A monoclonal antibody to the Hodgkin’s disease-associated antigen CD30 induces activation and long-term growth of human autoreactive gamma delta T cell clone. *Cell Immunol.* 156, 230–239 (1994).

56. Falini, B. et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfAMILY as a tool for diagnosis and immunotherapy. *Blood* 85, 1–14 (1995).

57. Lage, K. et al. A human phenome-interactome network of protein complexes encoded by the human genome. *Nature* 439, 771–778 (2006).

58. Bull, C. J. et al. Mouse genome informatics in a new age of biological inquiry. In *Proc. IEEE International Symposium on Bio-Informatics and Biomedical Engineering*, Arlington, VA, USA. https://doi.org/10.1109/BIBO.2000.889586–29–32 (2000).

59. Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. *Nucleic Acids Res.* 39, D691–D697 (2011).

60. Kanehisa, M., Goto, S., Furumichi, M. & Tanabe, M. KEGG for integration and interpretation of large-scale molecular data sets. *Nucleic Acids Res.* 40, D109–D114 (2012).

61. Raychaudhuri, S. et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet* 5, e1000334 (2009).

Acknowledgements

We thank the individuals who participated in this study and the staff at the Icelandic Patient Recruitment Center and the deCODE genetics core facilities. Further to all our colleagues who contributed to the data collection and phenotypic characterization of clinical samples as well as to the genotyping and analysis of the whole-genome association data. This research has been conducted using the UK Biobank Resource under Application Number 24711.

Author contributions

T.A.O., G.L.N. and I.J planned and performed the functional lab work. T.A.O., O.A.S., S.B., J.K.S., E.V.I., B.V.H., E.T., U.S.B., G.I.E., D.G., T.G., D.L., B.R.L., P.T.O., I.O., O.S. and I.J. carried out the subject ascertainment and recruitment. T.A.O., O.A.S., S.B., J.K.S., E.V.I., B.V.H., U.T., G.T., I.J. and K.S. designed the study and interpreted the results. T.A.O., U.S.B., G.I.E., D.G., T.G., D.L., B.R.L., P.T.O., I.O., O.S. and I.J. contributed to the peer review of this work. Peer reviewer reports are available.

Correspondence

T.A.O. and G.L.N. are to whom correspondence should be addressed. T.A.O. and G.L.N. and I.J. planned and performed the functional lab work. T.A.O., O.A.S., S.B., J.K.S., E.V.I., B.V.H., U.T., G.T., I.J. and K.S. designed the study and interpreted the results. T.A.O., U.S.B., G.I.E., D.G., T.G., D.L., B.R.L., P.T.O., I.O., O.S. and I.J. contributed to the peer review of this work. Peer reviewer reports are available.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41467-019-14144-8.

Peer review information

*Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
